Sandoz finalizes deal to acquire Just-Evotec Biologics
Swiss generics and biosimilars major Sandoz (SIX: SDZ) has announced a strategic agreement with Germany’s Evotec (XETRA: EVT) to acquire all issued and outstanding equity interests of Just-Evotec Biologics EU SAS (JEB SAS) which includes the Toulouse manufacturing site.
The proposed acquisition aligns with the Sandoz strategic objective of capitalizing on a projected ~$300 billion biosimilar market opportunity over the next 10 years1 and will provide Sandoz with own capabilities for the development and manufacturing of biosimilars using continuous manufacturing technology.
Following the announcement of a non-binding term sheet on July 30, 2025, Sandoz signs an agreement to acquire 100% of JEB SAS and an indefinite technology license for JEB’s continuous manufacturing platform, for an upfront cash consideration of approximately USD 350 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze